Skip to main content
Equibles
PULM logo

PULM · Pulmatrix, Inc.

Track PULM — free

Use PULM with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.52 +0.05 (+3.40%) At close · Sep 1
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“However, management believes that without the closing of the Merger, given our current cash position and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about our ability to continue as a going concern after the date that is one year from the date that these financial statements are issued.”
View the 10-Q filed Aug 13, 2026
Market Cap
$5.51M
Shares
3.65M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.47 Open$1.45 Day$1.45–1.49 52W close$1.19–5.19 Avg vol 30d12K Short int4K · 0.1% float · 1.0d Short vol79% Last earningsNov 13, 2024 DataMar 2022–Aug 2026 Filing10-Q · Aug 13

Raw chart and full-history price indicators begin at the captured split on Mar 1, 2022; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 16.3 · calm Equity put/call 0.70
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −32%
below
Price vs 50-day avg −10%
below
RSI (14) 39
neutral
MACD trend Negative
52-week position 7%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −16%
trailing
6-month return −28%
trailing
YTD return −34%
this year
Relative strength −42%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.11% of float · ▼ -75.2% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
15 holders — near 3-yr high, broad support
Squeeze score 23
low risk · 0–100
Fundamentals
Fair
Revenue growth +5070%
Y/Y
EPS growth +46%
Y/Y
Free cash flow $-5.8M
Balance sheet $39.3M
net debt
Quant / Vol
risk profile
Very High
Volatility 85%
annualized · 1-yr
Max drawdown −77%
past year
ATR 6.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−32% Bearish
Price vs 50-day avg
−10% Bearish
RSI (14)
39 Neutral
MACD trend
Negative Bearish
52-week position
7% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.11% of float · ▼ -75.2% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
15 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 7% Range high $5
vs 200-day avg -32% vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PULM
Pulmatrix, Inc.
this stock
$5.51M -34.1% +5069.9% — 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +20.1% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.77B +3.5% +20.8% 19.7 2.3%
ARGX
Argenx SE
 $64.16B +22.3% — — 1.9%
CSLLY
Csl Ltd
 $59.51B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
15
% held
9.2%
Net QoQ
+5.0K sh
Top holder
RENAISSANCE TECHNOLOGIES…
Held Float
View
Held by Funds
Fund positions
5
View
Short & Settlement
Short Interest Falling
Shares short
4.2K
Days to cover
1.0d
Change
-12.6K sh
View
Short Volume
Short vol %
79%
As of
Sep 1, 2026
Short Total
View
Fails to Deliver
FTD shares
276
Value
$458
As of
Aug 5, 2026
View
Off-Exchange
Off-exchange %
47.6%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$7.8M
Net income (FY)
$-5.2M
EPS diluted
$-1.41
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
10
View
Exempt Offerings
Offering
$1.0M
Filed
Apr 15, 2026
View
Earnings & Events
Earnings Calls
Last call
Nov 13, 2024
View

Performance

Raw-price comparisons begin at the captured split on Mar 1, 2022; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
PULM -5.2% -15.5% -28.3% -15.5% -34.1%
SPY +0.5% +1.2% +13.3% +2.7% +12.5%
vs SPY -5.6% -16.8% -41.6% -18.2% -46.6%
Key facts CIK 1574235 CUSIP 74584P301 13F (30d) 13 filings 13 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)